Trial Profile
A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms LEO
- 20 Oct 2015 Results published in the British Journal of Cancer
- 06 May 2013 Accrual to date is 76% according to United Kingdom Clinical Research Network record.
- 31 Mar 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.